ReviewJournal of tissue engineering
Current standards and ethical landscape of engineered tissues-3D bioprinting perspective.
Review in Journal of tissue engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- The Ethical Implications of Tissue Engineering for Regenerative Purposes: A Systematic Review.Tissue engineering. Part B, Reviews · 2023Pooled it
- Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues.Transplant international : official journal of the European Society for Organ Transplantation · 2022Pooled it
- Three-Dimensional Bioprinting in Reconstructive Plastic Surgery: A Comprehensive Review.Cells · 2026Review
- Engineering heterogeneous tissues and organs via multi-material bioprinting: Advances, challenges, and opportunities.Acta biomaterialia · 2026Review
- Manufacturing, Cell Regulation, and Coculture Strategies for Vascularization and Neural Innervation of Skeletal Muscle Tissue.Advanced healthcare materials · 2026Review
- Review
- "Bioprinting of Hair: How Far We Proceeded and What Needs to be Done".Biotechnology and bioengineering · 2026Review
- From Nature to Innovation: Exploring Natural Biopolymers in 3D Bioprinting for Bone Regeneration.ACS omega · 2026Article
- The Promise of 3D Biomaterial Bioprinting for Wound-Healing and Skin Tissue Restoration.Life (Basel, Switzerland) · 2026Review
- Soft Robotics and Advanced Technologies for Minimally Invasive Bioprinting: The Future of Internal Organ Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Human cell-derived dermal-specific interwoven extracellular matrix for diabetic wound healing.Acta biomaterialia · 2026Article
- Engineering ovarian tissue via biofabrication and 3D bioprinting: Challenges and emerging perspectives.Bioengineering & translational medicine · 2026Review
- Three-tier framework for high-throughput biofabrication: Integrating 3D bioprinting, assistive platforms, and translational opportunities.Bioactive materials · 2026Review
- Unconventional bioprinting modalities for advanced tissue biofabrication.Biomaterials · 2026Review
- From Design to Application: Advanced Cellulose Scaffolds for Engineered Tissue Regeneration.Polymers · 2026Review
- Advances in 3D Bioprinting: Materials, Processes, and Emerging Applications.Micromachines · 2026Review
- Emerging strategies for spinal cord injury repair: stem cells, extracellular vesicles, biomaterials, and neuromodulation.Frontiers in bioengineering and biotechnology · 2026Review
- Integrating 3D bioprinting and neural stem cell therapy for central nervous system repair: implications for regenerative neurosurgery.Frontiers in bioengineering and biotechnology · 2026Review
- Towards a bioengineered airway: advances in tracheal tissue engineering and biofabrication.Frontiers in cell and developmental biology · 2026Review
- Biomaterials in personalized drug delivery: innovations, challenges, and future directions.PeerJ · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tissue engineering is an evolving multi-disciplinary field with cutting-edge technologies and innovative scientific perceptions that promise functional regeneration of damaged tissues/organs. Tissue engineered medical products (TEMPs) are biomaterial-cell products or a cell-drug combination which is injected, implanted or topically applied in the course of a therapeutic or diagnostic procedure. Current tissue engineering strategies aim at 3D printing/bioprinting that uses cells and polymers to construct living tissues/organs in a layer-by-layer fashion with high 3D precision. However, unlike conventional drugs or therapeutics, TEMPs and 3D bioprinted tissues are novel therapeutics and need different regulatory protocols for clinical trials and commercialization processes. Therefore, it is essential to understand the complexity of raw materials, cellular components, and manufacturing procedures to establish standards that can help to translate these products from bench to bedside. These complexities are reflected in the regulations and standards that are globally in practice to prevent any compromise or undue risks to patients. This review comprehensively describes the current legislations, standards for TEMPs with a special emphasis on 3D bioprinted tissues. Based on these overviews, challenges in the clinical translation of TEMPs & 3D bioprinted tissues/organs along with their ethical concerns and future perspectives are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.